TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15111763

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tamoxifen after progression on anastrozole
Number of subjects: 60

Group type: COMPARATOR
Intervention: Anastrozole after progression on tamoxifen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Anastrozole-tamoxifen sequence
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamoxifen-anastrozole sequence
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tamoxifen followed by anastrozole
Number of subjects: 60
Study: 11230723

Group type: EXPERIMENTAL
Intervention: EPO treatment for ICU anemia
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Screening for iron, B12, and folate deficiency
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Iron studies
Number of subjects: 184
Study: 9204224

Group type: EXPERIMENTAL
Intervention: Self-administered food frequency questionnaire (FFQ)
Number of subjects: 95
Study: 8271800

Group type: EXPERIMENTAL
Intervention: Couples relapse prevention (RP) sessions
Number of subjects: 59

Group type: COMPARATOR
Intervention: Behavioral marital therapy (BMT) alone
Number of subjects: 59
Study: 3440931

Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Solution
Number of subjects: 20
Study: 31908219

Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block plus ERP
Number of subjects: 137

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137

Group type: COMPARATOR
Intervention: Bupivacaine TAP block
Number of subjects: 137
Study: 27755655

Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 18107

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18107
Study: 24855193

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 308

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 308
Study: 23288553

Group type: EXPERIMENTAL
Intervention: Antioxidants (alpha-lipoic acid, vitamin C, and vitamin E)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 21275549

Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg/week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (Vitamin D, alfacalcidol 1 μg/day)
Number of subjects: 40
Study: 19074924

Group type: EXPERIMENTAL
Intervention: QRS duration in patients with anterior acute myocardial infarction (AMI) with normal conduction
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: QRS duration in patients with anterior AMI with RBBB
Number of subjects: 12546

Group type: COMPARATOR
Intervention: QRS duration in patients with inferior AMI with normal conduction
Number of subjects: 12546

Group type: COMPARATOR
Intervention: QRS duration in patients with inferior AMI with RBBB
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: Increment of 20 ms increase in QRS duration for anterior AMI
Number of subjects: 12546

Group type: EXPERIMENTAL
Intervention: Changes in QRS duration over 60 min after fibrinolytic therapy
Number of subjects: 12546
Study: 17276969

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 14975462

Group type: EXPERIMENTAL
Intervention: Reduced-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatide (2 boluses of 180 microg/kg separated by 10 min, 2.0 microg/kg/min infusion)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Reduced-dose tenecteplase plus high-dose eptifibatide
Number of subjects: 140
Study: 11532409

Group type: EXPERIMENTAL
Intervention: SPI experience discussing pregnancy loss
Number of subjects: 38

Group type: COMPARATOR
Intervention: No SPI experience
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: SPI experience discussing rectal cancer
Number of subjects: 38
Study: 9541083

Group type: EXPERIMENTAL
Intervention: Combined operant programme plus cognitive/relaxation programme
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Operant programme plus attention-control
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Operant treatment alone
Number of subjects: 148

Group type: COMPARATOR
Intervention: Common individual rehabilitation therapy
Number of subjects: 148
Study: 7786689

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 266

Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 266
Study: 2853934

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg three times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg three times daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg three times daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Depot GnRH agonist alone
Number of subjects: 30
Study: 29694384

Group type: EXPERIMENTAL
Intervention: Major third
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fifth
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Psychoacoustic experiment
Number of subjects: 15
Study: 27196332

Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abacavir/Lamivudine + Dolutegravir (ABC/3TC + DTG)
Number of subjects: 0
Study: 25458542

Group type: EXPERIMENTAL
Intervention: AscPEG‐2L (PEG and ascorbic acid 2L)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: PiMg (sodium picosulfate and magnesium citrate 500 mL plus 2L of clear fluids)
Number of subjects: 292

Group type: COMPARATOR
Intervention: PEG‐ELS 4L (control group)
Number of subjects: 292
Study: 23548451

Group type: EXPERIMENTAL
Intervention: soft supportive foam orthotic (FO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: foam covered rigid self‐supporting plastic orthotic (PO)
Number of subjects: 30

Group type: COMPARATOR
Intervention: thin, non supportive orthotic (NO)
Number of subjects: 30
Study: 21282546

Group type: EXPERIMENTAL
Intervention: At-home symptom monitoring with clinician alerts for severe symptoms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 100
Study: 19877164

Group type: EXPERIMENTAL
Intervention: AbsPlus intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study: 16396766

Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m² on days 1-5 for three 21-day cycles, followed by thalidomide starting at 100 mg/day (escalated to 300 mg/day if tolerated) for up to 1 year.
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg/day, escalated to 300 mg/day if tolerated) for up to 1 year.
Number of subjects: 45
Study: 12755459

Group type: EXPERIMENTAL
Intervention: Day treatment plus contingency management (DT+)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Day treatment (DT)
Number of subjects: 127
Study: 10769525

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Thiopentone sodium
Number of subjects: 25
Study: 9191659

Group type: EXPERIMENTAL
Intervention: Impact (Sandoz Nutrition, Minneapolis, Minn), an immune-enhancing diet enhanced with omega-3 fatty acids, arginine, and RNA
Number of subjects: 50

Group type: COMPARATOR
Intervention: Replete (Clintec, Deerfield, Ill), standard high-protein diet
Number of subjects: 50
Study: 2201728

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0.25 mg triazolam
Number of subjects: 48
Study: 7011248

Group type: EXPERIMENTAL
Intervention: des-tyrosine-gamma-endorphin (DT gamma E)
Number of subjects: 10

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study: 31765805

Group type: EXPERIMENTAL
Intervention: RV-LV
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: QLV
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Combination of QLV and RV-LV
Number of subjects: 419
Study: 30695733

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-BF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28374511

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 331
Study: 25878305

Group type: EXPERIMENTAL
Intervention: Reconstruction plate
Number of subjects: 59

Group type: COMPARATOR
Intervention: Elastic stable intramedullary nailing
Number of subjects: 59
Study: 23497883

Group type: COMPARATOR
Intervention: Sunflower oil (SFO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mixed seed oil with added dimethylpolysiloxane (SOX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural antioxidants from olives (SOP)
Number of subjects: 20
Study: 21679268

Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) assessment among treatment seeking MA users
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 838
Study: 19365295

Group type: EXPERIMENTAL
Intervention: Prescription copayment (copay) policy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Income-based deductibles plus coinsurance (IBD) policy
Number of subjects: 0
Study: 17020440

Group type: EXPERIMENTAL
Intervention: Combined behavioural intervention (CBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CBI and medical management with placebos
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone with medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBI with medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naltrexone with CBI and medical management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall frequency of hospitalisation, emergency treatment, use of medication, detoxification
Number of subjects: 0
Study: 15496647

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 5 mg/kg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 15 mg/kg
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine doses of 11 to 68 mg/kg/day
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 112
Study: 11214809

Group type: EXPERIMENTAL
Intervention: Disclosure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collateral information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doll play
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affect
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expert judgments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Knowledge of sexual abuse literature
Number of subjects: 0

Group type: COMPARATOR
Intervention: Child-believing attitudes
Number of subjects: 0
Study: 9924334

Group type: EXPERIMENTAL
Intervention: Proxymetacaine 0.5%
Number of subjects: 53

Group type: COMPARATOR
Intervention: Amethocaine 0.5%
Number of subjects: 53
Study: 8555557

Group type: EXPERIMENTAL
Intervention: LVAD support
Number of subjects: 8
Study: 3214682

Group type: EXPERIMENTAL
Intervention: nandrolone decanoate + calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol + norethisterone acetate + calcium
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31923550

Group type: EXPERIMENTAL
Intervention: Patient-Activated Reliever-Triggered ICS (PARTICS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 33
Study: 29471905

Group type: EXPERIMENTAL
Intervention: Care sought from informal providers
Number of subjects: 1265

Group type: EXPERIMENTAL
Intervention: Overall population with TB symptoms
Number of subjects: 1265
Study: 26675536

Group type: EXPERIMENTAL
Intervention: Wound catheter placement plus standard postoperative analgesia
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard postoperative analgesia alone
Number of subjects: 92
Study: 25331922

Group type: EXPERIMENTAL
Intervention: Outpatient psychodynamic psychotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 90
Study: 24330605

Group type: EXPERIMENTAL
Intervention: RP-G28 (galacto-oligosaccharide) administered for 35 days
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 20542888

Group type: EXPERIMENTAL
Intervention: Intraoperative high-dose remifentanil (0.25 microg kg(‐1) min(‐1))
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraoperative low-dose remifentanil (0.1 microg kg(‐1) min(‐1))
Number of subjects: 50
Study: 18959453

Group type: EXPERIMENTAL
Intervention: Learning through music (n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Learning through speech (n = 18)
Number of subjects: 38
Study: 16846327

Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based stress-management intervention
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1085
Study: 14598189

Group type: EXPERIMENTAL
Intervention: Treadmill exercise at individual anaerobic threshold for 30 minutes
Number of subjects: 18
Study: 10945120

Group type: EXPERIMENTAL
Intervention: Mutual help group participation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Substance abuse education classes
Number of subjects: 0
Study: 8629387

Group type: EXPERIMENTAL
Intervention: Preoperative Transarterial Chemoembolization (TAE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 23
Study: 8479126

Group type: EXPERIMENTAL
Intervention: Low protein formula
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 24
Study: 3511931

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24681899

Group type: EXPERIMENTAL
Intervention: Emotion Dysregulation (ED)
Number of subjects: 180
Study: 27706948

Group type: EXPERIMENTAL
Intervention: UMPNL
Number of subjects: 73

Group type: COMPARATOR
Intervention: RIRS
Number of subjects: 73
Study: 24259189

Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 831

Group type: COMPARATOR
Intervention: Control (uncircumcised men)
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: As-treated analysis (circumcised men)
Number of subjects: 831

Group type: COMPARATOR
Intervention: As-treated analysis (uncircumcised men)
Number of subjects: 831
Study: 23860366

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy at 67 µg/kg/day for 1 year
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Baseline IGF-I levels
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: IGF-I responses after 1 year
Number of subjects: 110
Study: 21170205

Group type: EXPERIMENTAL
Intervention: Withania somnifera (500mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500mg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Withania somnifera and Terminalia arjuna (500mg/day each)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (capsules filled with flour)
Number of subjects: 40
Study: 17684475

Group type: EXPERIMENTAL
Intervention: NRTIs (nucleoside reverse transcriptase inhibitors)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: MTND1*LHON4216C
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: MTND2*LHON4917G
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: MTND1*LHON4216C after adjusting for confounders
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: MTND2*LHON4917G after adjusting for confounders
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Excluding 4917G individuals from analysis
Number of subjects: 250
Study: 16648247

Group type: EXPERIMENTAL
Intervention: Low-dose melatonin administration in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose melatonin administration in the afternoon/evening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bright light exposure (treatment of choice)
Number of subjects: 0
Study: 12819162

Group type: EXPERIMENTAL
Intervention: Preterm weaning strategy (n = 37)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Current best practice control group (n = 31)
Number of subjects: 68
Study: 11128877

Group type: EXPERIMENTAL
Intervention: Toluene exposure (measured by urinary excretion of unmodified toluene)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total Confusion Index
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Color Confusion Index
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cumulative toluene exposure (estimated as product of urinary excretion and previous exposure duration)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Occupational exposure limit proposed by the American Conference of Governmental Industrial Hygienists
Number of subjects: 49
Study: 8799521

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg day‐1 for 1 week)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporine alone
Number of subjects: 12
Study: 1365692

Group type: EXPERIMENTAL
Intervention: Surgery plus preoperative chemotherapy
Number of subjects: 77

Group type: COMPARATOR
Intervention: Immediate surgery
Number of subjects: 77
Study: 6404595

Group type: EXPERIMENTAL
Intervention: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable placebo
Number of subjects: 0
Study: 31612147

Group type: EXPERIMENTAL
Intervention: Propolis spray (3%) applied to cover the entire wound surface during dressing changes from week 0 until cicatrization or a maximum of 8 weeks.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Propolis spray (3%)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 31
Study: 29443664

Group type: EXPERIMENTAL
Intervention: Nusinersen (12 mg, intrathecal administration on days 1, 29, 85, and 274)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 126
Study: 27908454

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg intramuscular injection (days 0, 14, 28, then every 28 days thereafter)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Anastrozole 1 mg orally daily
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 524

Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 524
Study: 24911175

Group type: EXPERIMENTAL
Intervention: Exposure to female virtual stimuli (voice and image)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exposure to male virtual stimuli (voice and image)
Number of subjects: 0
Study: 22422103

Group type: EXPERIMENTAL
Intervention: Immunotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immuno-chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy added to chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study: 20404381

Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 3190

Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 3190
Study: 18321834

Group type: EXPERIMENTAL
Intervention: 12 dog visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 human visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: 12 quiet reading sessions
Number of subjects: 30
Study: 15772570

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d combined with MPA 2.5 mg/d (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg/d combined with MPA 5 mg/d (n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unopposed CEE 0.625 mg/d (n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 80
Study: 11819000

Group type: EXPERIMENTAL
Intervention: Prone positioning for 3 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Supine positioning for 3 hours
Number of subjects: 12
Study: 10406359

Group type: EXPERIMENTAL
Intervention: Vigabatrin 2 g daily
Number of subjects: 459

Group type: COMPARATOR
Intervention: Carbamazepine 600 mg daily
Number of subjects: 459
Study: 7776521

Group type: EXPERIMENTAL
Intervention: Intravenous injections of fentanyl 10‐13 micrograms.kg‐1 during lower abdominal surgery under light general anesthesia (halothane 0.3‐0.5% plus nitrous oxide and oxygen)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Lumbar epidural anesthesia (intermittent injections of 1.0% lidocaine) during lower abdominal surgery under light general anesthesia
Number of subjects: 4

Group type: COMPARATOR
Intervention: Thoracic epidural anesthesia (intermittent injections of 1.0% lidocaine) during upper abdominal surgery under light general anesthesia
Number of subjects: 4

Group type: COMPARATOR
Intervention: General anesthesia (halothane 1.0‐1.5% plus nitrous oxide and oxygen) during lower abdominal surgery
Number of subjects: 4
Study: 2222129

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of short half-life benzodiazepines
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Abrupt discontinuation of long half-life benzodiazepines
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Continued benzodiazepine use (n = 10)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Patients remaining free of benzodiazepines for at least 5 weeks
Number of subjects: 57
Study: 1093758

Group type: EXPERIMENTAL
Intervention: Active drugs
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 31209866

Group type: EXPERIMENTAL
Intervention: Random Forest algorithm
Number of subjects: 5050
Study: 27766711

Group type: EXPERIMENTAL
Intervention: Cold pressor conditioning stimulus (CPCS) at 4 °C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control session with water at 32 °C
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cold pressor conditioning stimulus (CPCS) and Control session
Number of subjects: 20
Study: 26605240

Group type: EXPERIMENTAL
Intervention: Memantine plus atypical antipsychotic
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus atypical antipsychotic
Number of subjects: 64